TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26106964

Group type: EXPERIMENTAL
Intervention: Thrombus localization in the main pulmonary arteries
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Thrombus localization in immobile patients
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: D-dimer levels and red blood cell distribution width in patients with thrombi in main pulmonary arteries
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Proximal thrombi associations
Number of subjects: 148
Study: 26108094

Group type: EXPERIMENTAL
Intervention: DXA (absolute BMD and Z-score)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: pQCT (volumetric BMD [vBMD] and stress-strain index [SSI])
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Laboratory evaluation and questionnaire administration
Number of subjects: 57
Study: 26109496

Group type: EXPERIMENTAL
Intervention: Serum oxytocin (OT) levels
Number of subjects: 552
Study: 26109579

Group type: EXPERIMENTAL
Intervention: Higher dietary glycemic index (GI)
Number of subjects: 87618

Group type: EXPERIMENTAL
Intervention: Higher consumption of dietary added sugars
Number of subjects: 87618

Group type: EXPERIMENTAL
Intervention: Higher consumption of lactose, fiber, nonjuice fruit, and vegetables
Number of subjects: 87618

Group type: EXPERIMENTAL
Intervention: Nonwhole/refined grain consumption
Number of subjects: 87618
Study: 26109588

Group type: EXPERIMENTAL
Intervention: guided high MI/half tPA (0.5 mg/kg tPA with guided high MI impulses)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: full-dose tPA (1.0 mg/kg tPA)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: guided high MI alone (without tPA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: half dose tPA (control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: guided high MI/half tPA
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: full-dose tPA
Number of subjects: 32
Study: 26109631

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m(2)), Cisplatin (75 mg/m(2)), and Cetuximab (250 mg/m(2) weekly with a loading dose of 400 mg/m(2)), followed by maintenance Cetuximab (500 mg/m(2) every 2 weeks)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin, and Cetuximab (TPEx regimen)
Number of subjects: 54
Study: 26109816

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus XELOX
Number of subjects: 197
Study: 26109878

Group type: EXPERIMENTAL
Intervention: sunitinib plus mFOLFOX6
Number of subjects: 191

Group type: COMPARATOR
Intervention: bevacizumab plus mFOLFOX6
Number of subjects: 191
Study: 26109993

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU/week for 6 months)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Vitamin D and Placebo
Number of subjects: 52
Study: 26110670

Group type: EXPERIMENTAL
Intervention: Different SMBG systems (7 systems tested)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison measurement with glucose oxidase method (YSI 2300 STAT Plus™)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison measurement with hexokinase method (cobas Integra(®) 400 Plus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ISO 15197:2003 accuracy criteria
Number of subjects: 0
Study: 26111071

Group type: EXPERIMENTAL
Intervention: Adjudication Committee (AC) review of suspected acute exacerbations (AExs)
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Adjudication Committee (AC) review of nonelective hospitalizations
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Adjudication Committee (AC) review of cases of bleeding
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Adjudication Committee (AC) role in determining adverse outcomes
Number of subjects: 1015
Study: 26111103

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis (guideline-recommended)
Number of subjects: 113
Study: 26111297

Group type: EXPERIMENTAL
Intervention: Positive for Giardia intestinalis (n=39)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Intensity of Giardia intestinalis infection
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fecal ELISA assay for G intestinalis
Number of subjects: 74
Study: 26111330

Group type: EXPERIMENTAL
Intervention: Limited dissection abdominoplasty
Number of subjects: 22

Group type: COMPARATOR
Intervention: Full dissection abdominoplasty
Number of subjects: 22
Study: 26111920

Group type: EXPERIMENTAL
Intervention: Two-step triage test including simple ultrasound-based rules
Number of subjects: 270

Group type: COMPARATOR
Intervention: Risk of Malignancy Index (RMI) with a cut-off value of 200
Number of subjects: 270
Study: 26112004

Group type: EXPERIMENTAL
Intervention: Oraxol (paclitaxel 150 mg/m(2) per day + HM30181A 15 mg/day)
Number of subjects: 43
Study: 26112099

Group type: EXPERIMENTAL
Intervention: Self-administered icatibant
Number of subjects: 170

Group type: COMPARATOR
Intervention: HCP-administered icatibant
Number of subjects: 170
Study: 26112223

Group type: EXPERIMENTAL
Intervention: Empiric oral antibiotic therapy
Number of subjects: 152
Study: 26113170

Group type: EXPERIMENTAL
Intervention: OPACH algorithm
Number of subjects: 175

Group type: COMPARATOR
Intervention: Visual inspection
Number of subjects: 175

Group type: COMPARATOR
Intervention: Participant logs
Number of subjects: 175
Study: 26114455

Group type: EXPERIMENTAL
Intervention: Forced aerobic exercise (FE) on a motorized stationary bicycle followed by upper-extremity repetitive task practice, 24 training sessions of 45 min each.
Number of subjects: 1
Study: 26114817

Group type: EXPERIMENTAL
Intervention: Intraoperative optical coherence tomography (OCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microscope-mounted spectral domain optical coherence tomography system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraoperative optical coherence tomography
Number of subjects: 0
Study: 26115532

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Unwanted treatment (any of the above therapies) in comorbidly depressed patients
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Treatment preference/disinclination
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Overall treatment preference
Number of subjects: 110
Study: 26115881

Group type: EXPERIMENTAL
Intervention: HCV treatment
Number of subjects: 124
Study: 26116126

Group type: EXPERIMENTAL
Intervention: GSK1034702 (5 mg oral dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: [(11)C]GSK1034702 (intravenous injection)
Number of subjects: 6
Study: 26116238

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with Paclitaxel and Trastuzumab for HER2-positive patients
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with Docetaxel and Epirubicin for HER2-negative patients
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Pathological complete response (pCR)
Number of subjects: 78
Study: 26116469

Group type: EXPERIMENTAL
Intervention: ERCP with cholangioscopy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: ERCP with cholangioscopy with biopsy sampling
Number of subjects: 57
Study: 26116658

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (Group 1; n = 27)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (Group 2; n = 20)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (Group 3; n = 24)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (all groups)
Number of subjects: 71
Study: 26116722

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26117461

Group type: EXPERIMENTAL
Intervention: ARTO system
Number of subjects: 11
Study: 26119560

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) administered according to the Southwest Oncology Group protocol.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Cytokine panel (nomogram CyPRIT) using urinary levels of nine inducible cytokines (IL-2, IL-6, IL-8, IL-18, IL-1ra, TRAIL, IFN-γ, IL-12[p70], and TNF-α).
Number of subjects: 130
Study: 26120369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26121348

Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 or 10 mg once daily
Number of subjects: 31
Study: 26121347

Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 or 10 mg daily (< 20 kg) or 10 or 20 mg daily (≥ 20 kg) for 8 weeks
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 109
Study: 26121349

Group type: EXPERIMENTAL
Intervention: Esomeprazole (2.5-10 mg once daily for 2 weeks, then weight-adjusted doses for 4 weeks)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Esomeprazole and Placebo
Number of subjects: 98
Study: 26121490

Group type: EXPERIMENTAL
Intervention: FAIM3:PLAC8 gene expression ratio
Number of subjects: 334
Study: 26123033

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study: 26123189

Group type: EXPERIMENTAL
Intervention: Carboplatin and nab-paclitaxel every 21 days
Number of subjects: 63
Study: 26123421

Group type: EXPERIMENTAL
Intervention: Impulse oscillometry (IOS) during bronchial challenge testing with inhaled methacholine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impulse oscillometry (IOS) during bronchial challenge testing with inhaled histamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spirometry (FEV1) during bronchial challenge testing with inhaled methacholine
Number of subjects: 0
Study: 26123563

Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26123660

Group type: EXPERIMENTAL
Intervention: sNox2-dp levels in patients with AF
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Pneumonia Severity Index score
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: History of paroxysmal AF
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: sNox2-dp levels
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: sNox2-dp levels at discharge
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Patients who returned to sinus rhythm
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: sNox2-dp levels in patients remaining in AF
Number of subjects: 432
Study: 26123926

Group type: EXPERIMENTAL
Intervention: Tivantinib (360 mg po bid)
Number of subjects: 22
Study: 26123937

Group type: EXPERIMENTAL
Intervention: Single-tablet FTC-RPV-TDF once daily for 28 days
Number of subjects: 100
Study: 26124071

Group type: EXPERIMENTAL
Intervention: Screening and brief intervention (SBI)
Number of subjects: 553
Study: 26124085

Group type: EXPERIMENTAL
Intervention: Focus group investigation
Number of subjects: 16
Study: 26124112

Group type: EXPERIMENTAL
Intervention: Whole-brain functional connectivity states computed within windows of 22.5 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatially restricted functional connectivity information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lowest task performance subjects
Number of subjects: 0
Study: 26124477

Group type: EXPERIMENTAL
Intervention: CS-1008 (tigatuzumab)
Number of subjects: 19
Study: 26126206

Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 64
Study: 26126668

Group type: EXPERIMENTAL
Intervention: HEV 239 vaccine
Number of subjects: 1278
Study: 26126727

Group type: EXPERIMENTAL
Intervention: Pasireotide LAR + Gemcitabine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study: 26129726

Group type: EXPERIMENTAL
Intervention: Experienced group of surgeons (n = 12)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Novice group of surgeons (n = 7)
Number of subjects: 19
Study: 26130053

Group type: EXPERIMENTAL
Intervention: Perimesencephalic SAH (PM-SAH)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Non-perimesencephalic SAH (NPM-SAH)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Fisher 3 blood pattern group
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Patients without Fisher 3 blood pattern
Number of subjects: 173
Study: 26130259

Group type: EXPERIMENTAL
Intervention: Soft tissue thickening in thin bone phenotypes after 8 weeks of healing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soft tissue dimensions in thick bone phenotypes after 8 weeks of healing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total tissue loss comparison between thin and thick bone phenotypes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dimensional alterations within the first 2 weeks of healing
Number of subjects: 0
Study: 26131835

Group type: EXPERIMENTAL
Intervention: Nonspecific complaints (NSC) patients
Number of subjects: 1210

Group type: EXPERIMENTAL
Intervention: Nonspecific complaints (NSC) patients with acute morbidity (heart failure and pneumonia)
Number of subjects: 1210

Group type: EXPERIMENTAL
Intervention: Nonspecific complaints (NSC) patients lacking acute morbidity but suffering from functional impairment or depression/anxiety
Number of subjects: 1210
Study: 26132091

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-CSCs
Number of subjects: 0
Study: 26132314

Group type: EXPERIMENTAL
Intervention: Rituximab (500 mg/m2), two infusions two weeks apart, followed by maintenance infusions after 3, 6, 10 and 15 months
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Rituximab (previously in a placebo group)
Number of subjects: 29
Study: 26132688

Group type: EXPERIMENTAL
Intervention: Avoidant personality disorder
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Emotional abuse (CTQ-SF subscale)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Emotional abuse moderating effect
Number of subjects: 279

Group type: COMPARATOR
Intervention: No avoidant personality disorder with emotional abuse
Number of subjects: 279
Study: 26133379

Group type: EXPERIMENTAL
Intervention: Active follow-up investigations at months 3, 6, 12, 24, and 36 after diagnosis.
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Passive follow-up investigations via registry offices and cancer registry.
Number of subjects: 2000
Study: 26133547

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (155 U every 12 weeks for 9 cycles)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 500
Study: 26133566

Group type: EXPERIMENTAL
Intervention: 2000 mg of ceftazidime + 500 mg of avibactam
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 3000 mg of ceftazidime + 1000 mg of avibactam
Number of subjects: 43
Study: 26133811

Group type: EXPERIMENTAL
Intervention: Lacosamide (100-800 mg/day)
Number of subjects: 376
Study: 26133904

Group type: EXPERIMENTAL
Intervention: Colon Capsule Endoscopy (CCE)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Crossover from CCE
Number of subjects: 329

Group type: COMPARATOR
Intervention: Crossover from Colonoscopy
Number of subjects: 329
Study: 26134834

Group type: EXPERIMENTAL
Intervention: Aggressive insulin delivery setting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medium insulin delivery setting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Conservative insulin delivery setting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Most aggressive setting
Number of subjects: 12

Group type: COMPARATOR
Intervention: All aggressiveness settings
Number of subjects: 12
Study: 26135098

Group type: EXPERIMENTAL
Intervention: Sodium picosulfate/magnesium citrate (SPMC)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Polyethylene glycol-based electrolyte solutions (PEG-ELS)
Number of subjects: 368
Study: 26135344

Group type: EXPERIMENTAL
Intervention: 1-cm larger waist circumference (WC) adjusted for BMI
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: 1-unit higher body mass index (BMI) adjusted for WC
Number of subjects: 1024
Study: 26135681

Group type: EXPERIMENTAL
Intervention: R1 resection margin
Number of subjects: 2815

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy in R1 patients
Number of subjects: 2815

Group type: COMPARATOR
Intervention: R0 resection margin
Number of subjects: 2815
Study: 26135770

Group type: EXPERIMENTAL
Intervention: Serum ischemia-modified albumin (IMA) concentrations in women with early pregnancy loss
Number of subjects: 180

Group type: COMPARATOR
Intervention: Serum ischemia-modified albumin (IMA) concentrations in healthy pregnant women
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Threshold of IMA >163 ng/mL
Number of subjects: 180
Study: 26136164

Group type: EXPERIMENTAL
Intervention: [(18)F]HX4 PET imaging
Number of subjects: 19
Study: 26136476

Group type: EXPERIMENTAL
Intervention: Pandemrix vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Focetria vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2009 A(H1N1) pandemic influenza infection
Number of subjects: 0
Study: 26137304

Group type: EXPERIMENTAL
Intervention: 2000 IU/day vitamin D supplementation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 25(OH)D ≥ 75 nmol/L
Number of subjects: 27
Study: 26137355

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 200 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 400 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26137358

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 25 mg/d for 1 week followed by placebo for 3 weeks (taper)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo for 4 weeks (abrupt discontinuation)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Desvenlafaxine 50 mg/d for 4 weeks (no discontinuation)
Number of subjects: 357
Study: 26137532

Group type: EXPERIMENTAL
Intervention: Escitalopram, sertraline or venlafaxine-ER for 8 weeks
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: MRI volumetric and connectivity measures
Number of subjects: 157
Study: 26137953

Group type: EXPERIMENTAL
Intervention: TC/HDL-C
Number of subjects: 1310432

Group type: EXPERIMENTAL
Intervention: Age, sex, and directly measured components of the standard lipid profile
Number of subjects: 1310432
Study: 26137961

Group type: EXPERIMENTAL
Intervention: CD200/BTLA deletions
Number of subjects: 1154

Group type: COMPARATOR
Intervention: Non-deleted cases
Number of subjects: 1154
Study: 26137969

Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: State Entropy (SE)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: BIS and SE
Number of subjects: 65
Study: 26137971

Group type: EXPERIMENTAL
Intervention: Clindamycin and metronidazole followed by vaginal EcoVag® capsules for 5 consecutive days after each antibiotic treatment.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clindamycin and metronidazole treatment together with prolonged administration of EcoVag® (10 consecutive days after each antibiotic treatment followed by weekly administration for next four months).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Extended fluconazole and EcoVag® treatment.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Extended fluconazole treatments only.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Frequency of isolation of any Lactobacillus species during the study.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Frequency of isolation of EcoVag® strains.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Change in sexual partner.
Number of subjects: 40
Study: 26137973

Group type: COMPARATOR
Intervention: Masked angry faces
Number of subjects: 37

Group type: COMPARATOR
Intervention: Unmasked angry faces
Number of subjects: 37

Group type: COMPARATOR
Intervention: Masked happy faces
Number of subjects: 37

Group type: COMPARATOR
Intervention: Unmasked happy faces
Number of subjects: 37

Group type: COMPARATOR
Intervention: Masked face processing across emotions
Number of subjects: 37
Study: 26138124

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26138630

Group type: EXPERIMENTAL
Intervention: New-onset atrial fibrillation (AF) during ARDS
Number of subjects: 282

Group type: COMPARATOR
Intervention: No new-onset atrial fibrillation (AF) during ARDS
Number of subjects: 282
Study: 26138702

Group type: EXPERIMENTAL
Intervention: Whole-grain crispbread low-fructose, low-calorie diet (CB-LCD)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Traditional low-calorie diet based on fructose-rich liquid meal replacements (LMR-LCD)
Number of subjects: 51
Study: 26138923

Group type: EXPERIMENTAL
Intervention: Individuals with a positive family history of dementia
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Vascular dementia (VaD)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Frontotemporal dementia (FTD)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Subtypes of dementia
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Family history of dementia
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Education level
Number of subjects: 576
Study: 26139558

Group type: EXPERIMENTAL
Intervention: MABp1 (1.25mg/kg body weight, four biweekly intravenous infusions)
Number of subjects: 7
Study: 26140502

Group type: COMPARATOR
Intervention: Medical therapy (n = 40)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) (n = 152)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Treatment crossover (n = 20)
Number of subjects: 212
Study: 26141008

Group type: EXPERIMENTAL
Intervention: Severe OSA (AHI ≥30)
Number of subjects: 825

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Gender, depression score, and BMI
Number of subjects: 825
Study: 26141371

Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anterior approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Direct lateral approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Operated legs
Number of subjects: 60